KalVista Pharmaceuticals, Inc. (LS:A2DG49) Financings
Financings
| Raise | Date |
|---|---|
| Convertible notes Closed: US$144M raised Use of proceeds: Continue advancing the global launch strategy for EKTERLY and building long-term growth | Nov 10, 2025 |
| Convertible Senior Notes due 2031 Announced: US$110M Use of proceeds: Working capital and general corporate purposes, including the commercialization of EKTERLY; possibly investments in or acquisitions of other companies or products | Sep 24, 2025 |